Pharmaceutical

Century secures $60m in stock sale and buys preclinical cell therapy biotech

Century Therapeutics will pay $35m upfront and an additional $10m milestone payments to acquire Clade Therapeutics.

Apr 13, 2024 - 00:00
Century secures $60m in stock sale and buys preclinical cell therapy biotech
Century Therapeutics will pay $35m upfront and an additional $10m milestone payments to acquire Clade Therapeutics.
Read the original article

Tags:

Previous Article

Candel wins FDA orphan drug designation for pancreatic cancer drug

Next Article

Moderna pauses plans to build mRNA facility in Kenya

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AGC and Asahi partner for clinical drug production in Seattle

AGC and Asahi partner for clinical drug production in S...

Aug 16, 2023

Listen: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business

Listen: Lilly’s Alzheimer’s success, a milestone FDA ap...

May 5, 2023

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

Adaptimmune leads in soft tissue sarcoma therapy with f...

Aug 11, 2024